A regulatory strategy for medical devices refers to the early-defined, reasoned sequence of decisions by which a manufacturer achieves market access for a product: classification, choice of conformity assessment procedure, generation of clinical evidence, selection of the Notified Body, timeline, and sequence of target markets. The term is not a legal category but a planning instrument that translates the requirements of Regulation (EU) 2017\/745 into project logic. It should be used with caution, as medical devices are not officially approved in the Union but are CE-marked after a conformity assessment procedure. A robust strategy therefore distinguishes between conformity assessment, certification by a Notified Body, and official registration. <\/p>\n
The starting point is classification according to Annex VIII, which is based on the intended purpose and is carried out separately for each product. The class determines the applicable procedure according to Article 52: manufacturers of Class I products without a sterile function, measuring function, or reusable surgical instruments declare conformity themselves after preparing the technical documentation according to Annexes II and III, while higher classes require the involvement of a Notified Body according to Annexes IX, X, or XI. <\/p>\n
Strategically, the intended purpose remains the most effective control instrument: any expansion of indications, patient groups, or user groups simultaneously changes the class, procedure, and evidence requirements.<\/p>\n
Clinical evidence is the part of the strategy with the longest lead time. It is based on a clinical evaluation according to Article 61 with a plan according to Annex XIV Part A and determines early on whether own clinical investigations according to Article 62 are necessary or whether literature and equivalence data are sufficient. <\/p>\n
The strategy must also plan for the period after certification, as clinical post-market surveillance and reporting cycles for market observation permanently tie up resources. Those who only consider evidence generation up to the certificate will create gaps at the first recertification. <\/p>\n
The selection of the Notified Body depends on its scope of designation for the relevant product codes, its capacity, and its deadlines. For legacy devices, the extended transitional provisions of Article 120 apply: certificates issued under the former directives remain valid until December 31, 2027, for Class III products and implantable Class IIb products, and until December 31, 2028, for other Class IIb products, Class IIa products, and Class I products placed on the market in sterile condition or with a measuring function. <\/p>\n
This extension was subject to strict deadlines: establishment of a quality management system according to Article 10(9) by May 26, 2024, formal application to a Notified Body by May 26, 2024, and written agreement by September 26, 2024. The prerequisite remains that no significant changes to the design and intended purpose occur and no unacceptable risk exists. <\/p>\n
After or in parallel with CE marking, the question of the sequence of further markets arises. In Switzerland, manufacturers without a registered office in the country require an authorized representative in Switzerland, whose mandate must be agreed upon in writing, according to Article 51 of the Medical Devices Ordinance. In the United States, pathways include a Premarket Notification via 510(k) for most Class II products, a De Novo application for novel products without a predicate device, and a Premarket Approval for Class III products. <\/p>\n
For medicinal products, an authority grants a marketing authorization, which is tied to a dossier with a defined structure and official assessment procedures. For medical devices, however, no authority examines the product before it is placed on the market; the Notified Body merely certifies conformity with the requirements, and responsibility for the declaration of conformity remains with the manufacturer. <\/p>\n
Registration must also be distinguished: the registration of economic operators and products and the assignment of the unique registration number according to Article 31 are administrative acts without a statement of conformity. Anyone who presents them as approval makes misleading claims within the meaning of Article 7. <\/p>\n
The regulatory strategy defines which clinical data must be available when, and thus directly determines the design and timing of studies. An initial study with a small sample size may be sufficient to demonstrate technical feasibility and handling, while proof of clinical benefit for a Class III product often requires a controlled study with clinically relevant endpoints. If this is only decided after the first contact with the Notified Body, certification dates will be delayed by years. <\/p>\n
The international scope must also be included in the planning, because endpoints, comparator treatment, and study population determine the usability of the data in other jurisdictions. Full-service CROs like Mediconomics support manufacturers in aligning evidence requirements, study planning, and documentation requirements so that the collected data supports both the clinical evaluation and subsequent post-market surveillance. <\/p>\n
Is there an approval for medical devices in the European Union?<\/strong><\/p>\n No. Market access is achieved through a conformity assessment procedure according to Article 52 and CE marking. There is no official authorization before placing on the market; exceptions only concern special cases such as temporary national derogations according to Article 59. <\/p>\n When should the strategy be defined?<\/strong><\/p>\n As early as possible, ideally with the definition of the intended purpose. Classification, procedure selection, and evidence requirements depend directly on it, and late changes devalue already collected data. <\/p>\n Can the Notified Body advise on the strategy?<\/strong><\/p>\n Notified Bodies are not permitted to provide advice that compromises their impartiality. They clarify procedural questions but do not replace a manufacturer’s own regulatory planning. <\/p>\n A regulatory strategy for medical devices refers to the early-defined, reasoned sequence of decisions by which a manufacturer achieves market access for a product: classification, choice of conformity assessment procedure, generation of clinical evidence, selection of the Notified Body, timeline, and sequence of target markets. The term is not a legal category but a planning […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[24],"class_list":["post-7726","glossary","type-glossary","status-publish","hentry","glossary-cat-medizinprodukte-ivd"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7726","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":0,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/7726\/revisions"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=7726"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=7726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory References<\/h2>\n
\n